| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Net income | -53.1 | -44.9 |
| EPS (diluted, $ a share) | $-0.28 | $-0.44 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
10-Q filed with the SEC, NASDAQ: CABA. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Cabaletta Bio, Inc.: key numbers
- Share price
- $1.11Close, Nov 16
- Market cap
- $239M
- Shares outstanding
- 215.72MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Biological Products, (No Diagnostic Substances)SIC 2836
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Cabaletta Bio, Inc.
All →Cabaletta Bio Clinical Trial Data
Cabaletta Bio presented Phase 1/2 clinical data for rese-cel (CABA-201) at the ACR Convergence 2026 meeting, demonstrating durable, immunomodulator-free responses across multiple autoimmune diseases. Key results showed 100% of dermatomyositis patients maintained moderate-to-major improvement scores through one year and 100% of biopsied lupus nephritis patients achieved DORIS remission. The company plans to report topline registrational data in H2 2027 and submit a Biologics License Application in Q1 2028.
“In three different autoimmune diseases where patients are at risk of severe disability, end-organ damage, and increased risk of death despite current therapies, a single weight-based dose of rese-cel delivered immunomodulator-free clinical improvements that were durable through at least one year with a favorable benefit-risk profile.”
David J. Chang, M.D., Chief Medical Officer of Cabaletta
“We believe these emerging data reinforce the potential of rese-cel to deliver an immune reset that leads to durable efficacy with a favorable benefit-risk profile for autoimmune disease patients.”
David J. Chang, M.D., Chief Medical Officer of Cabaletta
Cabaletta Bio Financial Results
Cabaletta Bio reported third quarter 2026 financial results, highlighting a cash position of $299.4 million which extends its operational runway into Q1 2028. The company announced plans for a BLA submission for rese-cel in myositis in Q1 2028 and initiated a second registrational study in systemic sclerosis. Management noted a recent increase in enrollment activity following a slower period in Q3 2026.
- Term
- Q3 2026
“We are encouraged by the favorable benefit-risk profile observed with rese-cel to date as we made deliberate choices, including construct design, standard and well-characterized manufacturing, and weight-based dosing, from the outset of its development to prioritize patient safety.”
Steven Nichtberger, M.D., Chief Executive Officer of Cabaletta
“We are now seeing increased enrollment and screening activity, with multiple patients enrolled in the past few weeks in the registrational adult myositis study, after a slower period in 3Q26 that we believe was influenced by patient and physician caution following recently reported safety events from others in the field.”
Steven Nichtberger, M.D., Chief Executive Officer of Cabaletta
Cabaletta Bio Capital Raise of $128M
Cabaletta Bio announced the completion of warrant exercises from its June 2025 public offering, resulting in total aggregate gross proceeds of approximately $128.2 million. The warrants, which had an exercise price of $2.50 per share, expired on September 12, 2026, with the vast majority of exercises occurring between July 1, 2026, and the expiration date.
- Value
- $128M